PGEN - Precigen soars 28% on positive AG019 Actobiotics data in type 1 diabetes

Precigen's (PGEN) soars 28% premarket after its wholly-owned subsidiary, Precigen ActoBio reported positive topline results for Phase 1b/2a clinical study investigating AG019 ActoBiotics for the treatment of recent-onset type 1 diabetes (T1D).The primary endpoint of treatment-emerging adverse events (TEAEs) up to 6 months post treatment initiation was met.Phase 1b oral AG019 monotherapy:Following a single 8-week treatment cycle, 56% of adult patients (5 of 9) showed stabilization or increase of C-peptide levels during the first 6 months post treatment initiation.AG019 monotherapy induced antigen-specific tolerance in conjunction with the reduction of disease-specific T cell responses 6 months post treatment initiation.Preproinsulin ((PPI))-specific CD8+ T cells in circulation were reduced in 87% of patients (7 of 8) at 3 months and in 83% of patients (5 of 6) at 6 months.An increase in the frequency of PPI-specific memory Tregs and CD4+ Tr1 cells was observed in 75% (3/4) of adults at 6 months and in 100%

For further details see:

Precigen soars 28% on positive AG019 Actobiotics data in type 1 diabetes